4,640 Shares in Insmed, Inc. $INSM Acquired by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,640 shares of the biopharmaceutical company’s stock, valued at approximately $759,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Insmed during the fourth quarter worth about $506,625,000. RTW Investments LP raised its position in Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after buying an additional 1,758,321 shares during the last quarter. Orbis Allan Gray Ltd acquired a new stake in Insmed in the 2nd quarter valued at approximately $153,389,000. State Street Corp boosted its position in Insmed by 30.6% during the 4th quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after acquiring an additional 1,217,390 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares during the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently commented on INSM. Bank of America lifted their target price on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, June 10th. JPMorgan Chase & Co. lowered their price target on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a research report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. Finally, Mizuho set a $192.00 price target on Insmed in a research report on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $211.05.

Insiders Place Their Bets

In other news, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the sale, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 1,806 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total value of $173,050.92. Following the completion of the transaction, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 54,590 shares of company stock worth $5,793,738. Corporate insiders own 2.10% of the company’s stock.

Insmed Price Performance

Shares of NASDAQ:INSM opened at $109.81 on Thursday. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $23.80 billion, a PE ratio of -19.10 and a beta of 0.78. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a 50-day moving average price of $105.54 and a two-hundred day moving average price of $136.60.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same quarter last year, the company earned ($1.42) earnings per share. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. Equities analysts forecast that Insmed, Inc. will post -2.52 EPS for the current year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.